Literature DB >> 9100571

Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension?

R López-Velasco1, H F Escobar-Morreale, B Vega, E Villa, J M Sancho, J L Moya-Mur, R García-Robles.   

Abstract

To evaluate the relative contributions of past or present GH hypersecretion and of hypertension to the cardiac abnormalities present in acromegaly, we have studied the serum GH and insulin-like growth factor I concentrations, systolic and diastolic blood pressures, and morphological and functional cardiac indexes as measured by echocardiography-Doppler, in 39 patients with active or cured acromegaly, 16 hypertensive controls, and 17 normotensive controls. Hypertension was present in 42.8% of patients with active acromegaly and in 28.0% of patients in which acromegaly was cured. Hypertension was independently related to an increase in indexes of cardiac morphology (left ventricular mass, left ventricular posterior wall thickness, interventricular septum thickness, relative wall thickness with respect to the diastolic diameter of the left ventricle, and left atrial end-systolic diameter), systolic function (stroke volume, fractional shortening, and end-systolic stress), and diastolic function (isovolumic relaxation time and maximal late diastolic flow velocity) and to a reduction in the early to late maximal diastolic flow velocity ratio. Acromegaly was related to an increase in left ventricular mass, stroke volume, cardiac output, and isovolumic relaxation time, which were independent from the presence of hypertension. End-systolic stress was reduced by acromegaly. In the five patients in which active acromegaly was successfully treated, left ventricular mass and left ventricular posterior wall thickness were reduced 1 yr later. In conclusion, the asymptomatic morphological and functional cardiac abnormalities present in acromegalic patients are independently related to acromegaly and hypertension, pointing to the existence to a specific acromegalic myocardiopathy that might be aggravated by the coexistence of hypertension.

Entities:  

Mesh:

Year:  1997        PMID: 9100571     DOI: 10.1210/jcem.82.4.3876

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

Review 1.  Endocrine Tumors Causing Arterial Hypertension: Pathophysiological Mechanisms and Clinical Implications.

Authors:  Agata Buonacera; Benedetta Stancanelli; Lorenzo Malatino
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-04-12

2.  Recombinant human GHRH(1-44)NH2: clinical utility and therapeutic development program.

Authors:  M R Ehlers
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 3.  Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.

Authors:  Ana M Ramos-Leví; Mónica Marazuela
Journal:  Endocrine       Date:  2017-01-02       Impact factor: 3.633

4.  Heart rate variability is reduced in acromegaly patients and improved by treatment with somatostatin analogues.

Authors:  A Comunello; F Dassie; C Martini; E De Carlo; R Mioni; M Battocchio; A Paoletta; F Fallo; R Vettor; P Maffei
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

5.  Growth hormone status predicts left ventricular mass in patients after cure of acromegaly.

Authors:  Tamara L Wexler; Ronen Durst; David McCarty; Michael H Picard; Lindsay Gunnell; Zehra Omer; Pouneh Fazeli; Karen K Miller; Anne Klibanski
Journal:  Growth Horm IGF Res       Date:  2010-07-03       Impact factor: 2.372

Review 6.  The Somatotropic Axis in Human Aging: Framework for the Current State of Knowledge and Future Research.

Authors:  Sofiya Milman; Derek M Huffman; Nir Barzilai
Journal:  Cell Metab       Date:  2016-06-14       Impact factor: 27.287

Review 7.  Acromegalic cardiomyopathy: Epidemiology, diagnosis, and management.

Authors:  Ajay N Sharma; Marilyn Tan; Ezra A Amsterdam; Gagan D Singh
Journal:  Clin Cardiol       Date:  2018-03-25       Impact factor: 2.882

Review 8.  Management of acromegaly: is there a role for primary medical therapy?

Authors:  Zachary M Bush; Mary Lee Vance
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

9.  Effect of growth hormone treatment on diastolic function in patients who have developed growth hormone deficiency after definitive treatment of acromegaly.

Authors:  Pouneh K Fazeli; Jonathan G Teoh; Eleanor L Lam; Anu V Gerweck; Tamara L Wexler; Eliza P Teo; Brian M Russell; Ronen Durst; David McCarty; Rory B Weiner; Michael H Picard; Anne Klibanski; Karen K Miller
Journal:  Growth Horm IGF Res       Date:  2015-12-03       Impact factor: 2.372

10.  Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study.

Authors:  G Lombardi; A Colao; P Marzullo; B Biondi; E Palmieri; S Fazio
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.